<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03444818</url>
  </required_header>
  <id_info>
    <org_study_id>E6007-CP3</org_study_id>
    <secondary_id>2017-004119-38</secondary_id>
    <nct_id>NCT03444818</nct_id>
  </id_info>
  <brief_title>A Study to Determine the Absorption, Metabolism, and Excretion of [14C]-E6007 After a Single Oral Administration in Healthy Male Participants</brief_title>
  <official_title>A Phase I, Open-label, Study to Determine the Absorption, Metabolism, and Excretion of [14C]-E6007 After a Single Oral Administration in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EA Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted to evaluate the absorption, metabolism, and excretion of a
      single oral dose of [14C]-E6007 in healthy male participants.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2018</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum concentration (Cmax) of E6007 derived from whole blood</measure>
    <time_frame>Predose and 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72 and 96 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve (AUC) from time zero to infinity (AUC[0-âˆž]) postdose of E6007</measure>
    <time_frame>Predose and 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72 and 96 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total radioactivity derived from whole blood</measure>
    <time_frame>Up to 11 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total radioactivity in urine</measure>
    <time_frame>Up to 11 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total radioactivity in feces</measure>
    <time_frame>Up to 11 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with any serious adverse event</measure>
    <time_frame>Up to 11 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with any non-serious adverse event</measure>
    <time_frame>Up to 11 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Healthy Male Participants</condition>
  <arm_group>
    <arm_group_label>[14C]-E6007</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single oral dose of 60 milligrams (mg) of [14C]-E6007.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]-E6007</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>[14C]-E6007</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  30 to 55 years of age

          -  Body mass index between 18.5 and 30.0 kilograms per meters squared (kg/m^2), and a
             total body weight between 50 and 100 kilograms (kg)

          -  In good health, determined by no clinically significant findings from medical history,
             physical examination, 12 lead electrocardiogram, vital sign measurements, and clinical
             laboratory evaluations

          -  Males will agree to use contraception

          -  Able to comprehend and willing to sign an informed consent form and to abide by the
             study restrictions

        Exclusion Criteria:

          -  Significant history or clinical manifestation of any metabolic, allergic,
             dermatological, hepatic, renal, haematological, pulmonary, cardiovascular,
             gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder

          -  History of significant hypersensitivity, intolerance, or allergy to any drug compound,
             food, or other substance

          -  History of stomach or intestinal surgery or resection that would potentially alter
             absorption and/or excretion of orally administered drugs (uncomplicated appendectomy,
             and hernia repair will be allowed)

          -  Significant history or clinical manifestation of hemorrhoids

          -  History of alcoholism or drug/chemical abuse within 2 years prior to Check-in

          -  Positive hepatitis panel and/or positive human immunodeficiency virus test

          -  Participation in a clinical study involving administration of an investigational drug
             (new chemical entity) in the past 90 days prior to Check-in

          -  Use or intend to use any prescription medications/products within 14 days prior to
             Check-in

          -  Participants in receipt of a live vaccine within 30 days prior to the first dose
             administration or who plan to receive a live vaccine during the study and for 14 days
             after the dose of study drug

          -  Use of tobacco or nicotine containing products within 3 months prior to Check-in

          -  Receipt of blood products within 2 months prior to Check-in

          -  Donation of blood from 3 months prior to Screening, plasma from 2 weeks prior to
             Screening, or platelets from 6 weeks prior to Screening

          -  Participants with exposure to significant diagnostic or therapeutic radiation or
             current employment in a job requiring radiation exposure monitoring within 12 months
             prior to Check-in

          -  Participants who have participated in any clinical trial involving a radiolabelled
             investigational product within 12 months prior to Check-in
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Public Relations Group</last_name>
    <phone>81-(0)3-6280-9600</phone>
    <email>contact_ea@eapharma.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Covance Clinical Research Unit (CRU) Ltd.</name>
      <address>
        <city>Leeds</city>
        <state>West Yorkshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2018</study_first_submitted>
  <study_first_submitted_qc>February 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2018</study_first_posted>
  <last_update_submitted>February 19, 2018</last_update_submitted>
  <last_update_submitted_qc>February 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>E6007</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Radioactivity</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

